Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: Implications for rational design of novel and follow-on therapeutic antibodies

被引:26
作者
Kumar, Sandeep [1 ]
Mitchell, Mark A. [2 ]
Rup, Bonita [3 ]
Singh, Satish K. [1 ]
机构
[1] Pfizer Inc, Biotherapeut Pharmaceut Sci Res & Dev, Chesterfield, MO 63017 USA
[2] Pfizer Inc, Pharmaceut Sci Business Technol, St Louis, MO 63141 USA
[3] Pfizer Inc, Prot Bioanalyt, Andover, MA USA
关键词
mAbs; immune epitopes; bioinformatics; drug; protein aggregation; proteins; computer-aided drug design; Biopharamaceutics; HUMAN INTERFERON-BETA; MONOCLONAL-ANTIBODY; SEQUENCE DETERMINANTS; IMMUNOGENICITY; PREDICTION; PEPTIDES; PROTEINS; INSULIN; BIOTHERAPEUTICS; SEGMENTS;
D O I
10.1002/jps.23169
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aggregation and unwanted immunogenicity are hurdles to avoid in successful commercial development of antibody-based therapeutics. In this article, the relationship between aggregation-prone regions (APRs), capable of forming cross-beta motifs/amyloid fibrils, and major histocompatibility complex class II-restricted human leukocyte antigen (HLA)-DR-binding T-cell immune epitopes (TcIEs) is analyzed using amino acid sequences of 25 therapeutic antibodies, 55 TcIEs recognized by T-regulatory cells (tregitopes), 1000 randomly generated 15-residue-long peptides, 2257 human self-TcIEs (autoantigens), and 11 peptides in HLA-peptide cocrystal structures. Sequence analyses from these diverse sources consistently show a high level of correlation between APRs and TcIEs: approximately one-third of TcIEs contain APRs, but the majority of APRs occur within TcIE regions (TcIERs). Tregitopes also contain APRs. Most APR-containing TcIERs can bind multiple HLA-DR alleles, suggesting that aggregation-driven adverse immune responses could impact a broad segment of patient population. This article has identified common molecular sequencestructure loci that potentially contribute toward both manufacturability and safety profiles of the therapeutic antibodies, thereby laying a foundation for simultaneous optimization of these attributes in novel and follow-on candidates. Incidence of APRs within TcIERs is not special to biotherapeutics, self-TcIEs from human proteins, involved in various diseases, also contain predicted APRs and experimentally proven amyloid-fibril-forming peptide sequence portions.(C) 2012 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 101:26862701, 2012
引用
收藏
页码:2686 / 2701
页数:16
相关论文
共 72 条
[1]   Aggregation in Protein-Based Biotherapeutics: Computational Studies and Tools to Identify Aggregation-Prone Regions [J].
Agrawal, Neeraj J. ;
Kumar, Sandeep ;
Wang, Xiaoling ;
Helk, Bernhard ;
Singh, Satish K. ;
Trout, Bernhardt L. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (12) :5081-5095
[2]  
Baker Matthew P, 2010, Self Nonself, V1, P314, DOI 10.4161/self.1.4.13904
[3]   Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity [J].
Barbosa, MDFS ;
Vielmetter, J ;
Chu, S ;
Smith, DD ;
Jacinto, J .
CLINICAL IMMUNOLOGY, 2006, 118 (01) :42-50
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies [J].
Brennan, Frank R. ;
Morton, Laura Dill ;
Spindeldreher, Sebastian ;
Kiessling, Andrea ;
Allenspach, Roy ;
Hey, Adam ;
Muller, Patrick Y. ;
Frings, Werner ;
Sims, Jennifer .
MABS, 2010, 2 (03) :233-255
[6]   Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions: Part 1. Unfolding, Colloidal Interactions, and Formation of High-Molecular-Weight Aggregates [J].
Brummitt, Rebecca K. ;
Nesta, Douglas P. ;
Chang, Liuquan ;
Chase, Susan F. ;
Laue, Thomas M. ;
Roberts, Christopher J. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (06) :2087-2103
[7]   Prediction of Immunogenicity of Therapeutic Proteins Validity of Computational Tools [J].
Bryson, Christine J. ;
Jones, Tim D. ;
Baker, Matthew P. .
BIODRUGS, 2010, 24 (01) :1-8
[8]  
Buck PM, 2011, THERAPEUTIC IN PRESS
[9]   Taking immunogenicity assessment of therapeutic proteins to the next level [J].
Buettel, I. C. ;
Chamberlain, P. ;
Chowers, Y. ;
Ehmann, F. ;
Greinacher, A. ;
Jefferis, R. ;
Kramer, D. ;
Kropshofer, H. ;
Lloyd, P. ;
Lubiniecki, A. ;
Krause, R. ;
Mire-Sluis, A. ;
Platts-Mills, T. ;
Ragheb, J. A. ;
Reipert, B. M. ;
Schellekens, H. ;
Seitz, R. ;
Stas, P. ;
Subramanyam, M. ;
Thorpe, R. ;
Trouvin, J. -H. ;
Weise, M. ;
Windisch, J. ;
Schneider, C. K. .
BIOLOGICALS, 2011, 39 (02) :100-109
[10]   Design of therapeutic proteins with enhanced stability [J].
Chennamsetty, Naresh ;
Voynov, Vladimir ;
Kayser, Veysel ;
Helk, Bernhard ;
Trout, Bernhardt L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (29) :11937-11942